SCHEMBL12376560

SCHEMBL12376560

COc1ccc2c(c1)nc(C(C)C)n2C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.53
ALDH1A1 P00352 7/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ACSS2 Q9NR19 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 2/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
FGFR1 P11362 2/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CNR2 P34972 1/20 0.43
TP53 P04637 1/20 0.43
ACACB O00763 1/20 0.42
GFER P55789 1/20 0.42
POLB P06746 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21540402 0.86 ALDH1A1 (0.51) PIK3CDALDH1A1SMN1; SMN2ACSS2TDP1
SCHEMBL1463815 0.79 CYP3A4 (0.53) PIK3CDALDH1A1SMN1; SMN2KDM4EPOLB
SCHEMBL14344232 0.78 MAPT (0.69) PIK3CDALDH1A1SMN1; SMN2ACSS2TDP1
SCHEMBL12317672 0.78 KDM4E (0.48) ACSS2MAPTFGFR1KDM4ENPC1
SCHEMBL12269122 0.78 HDAC6 (0.43) ALDH1A1SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL25443596 0.77 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2ACSS2TDP1MAPT
SCHEMBL3613367 0.77 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2TDP1MAPTFGFR1
SCHEMBL3965377 0.77 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2ACSS2TDP1MAPT
SCHEMBL12869467 0.77 ESR1 (0.46) SMN1; SMN2FGFR1KDM4ECNR2KMT2A
SCHEMBL4790064 0.77 MEN1 (0.42) PIK3CDALDH1A1MAPTPIK3CBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201607-A1 FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck, Sharp & Dohme, Corp. 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201607-A1 FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, OPRM1 PIK3CD 767/4885ALDH1A1 2852/4885SMN1; SMN2 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.